Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.43 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.43 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22987708 | 0.89 | NR1H2 (0.48) | ADORA3ADORA1ADORA2AMAPTXDH | |
| SCHEMBL22987510 | 0.87 | NR1H2 (0.50) | ADORA3ADORA1ADORA2AXDHTP53 | |
| SCHEMBL22987462 | 0.86 | KDM4E (0.50) | POLBKDM4EALDH1A1ADORA3ADORA1 | |
| SCHEMBL22988147 | 0.86 | KDM4E (0.52) | POLBKDM4EALDH1A1ADORA3ADORA1 | |
| SCHEMBL22987426 | 0.85 | KDM4E (0.51) | POLBKDM4EALDH1A1ADORA3ADORA1 | |
| SCHEMBL22987552 | 0.85 | KDM4E (0.51) | POLBKDM4EALDH1A1ADORA3ADORA1 | |
| SCHEMBL22979677 | 0.84 | KDM4E (0.50) | POLBKDM4EALDH1A1ADORA3ADORA1 | |
| SCHEMBL22988097 | 0.83 | PDPK1 (0.40) | ADORA3ADORA1ADORA2A | |
| SCHEMBL22987474 | 0.83 | ADORA3 (0.43) | POLBKDM4EALDH1A1ADORA3ADORA1 | |
| SCHEMBL22988095 | 0.82 | KDM4E (0.48) | POLBKDM4EALDH1A1ADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | disclosed |
| WO-2021028382-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | AHR, HRH4, HRH1 | POLB 4033/4885KDM4E 1364/4885ALDH1A1 597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.